ArticleCancer science2017

Phase I clinical trial of cell division associated 1 (CDCA1) peptide vaccination for castration resistant prostate cancer.

Wataru Obara et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.